Posted by Michael Wonder on 19 Mar 2020
ICER releases draft evidence report on obeticholic acid for non-alcoholic steatohepatitis
19 March 2020 - Public comment period on preliminary draft now open until 24 June 2020; requests to make oral comment during public meeting also being accepted.
The Institute for Clinical and Economic Review (ICER) today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of obeticholic acid (Intercept Pharmaceuticals) for the treatment of non-alcoholic steatohepatitis.
This preliminary draft marks the midpoint of ICER’s process of assessing these treatments, and the findings within this document should not be interpreted to be ICER’s final conclusions.
